An external collaboration platform in R&D, education, technology, and government affairs, iDREAM is an AstraZeneca initiative being implemented through local bio-hubs across our Emerging Markets. The initiative was launched in 2018 as part of our ambitious drive to create integrated science ecosystems across our International Region. These bio-hubs improve local capacity for R&D to address local needs and reinforce our commitment to expand the frontiers of science, creating innovative solutions to improve patients’ lives.
In 2018, AstraZeneca launched iDREAM hubs in Russia, Brazil and Taiwan, and in 2019 implemented hubs in China, Argentina and India. See below the important collaboration agreements signed so far:
- Russia, July 2018 – We launched our Russia iDREAM hub with the signing of a Memorandum of Understanding (MOU) with the Skolkovo Institute of Science and Technology (Skoltech), which is focused on education of highly-skilled professionals for the pharmaceutical industry as well as joint research activities. Previously, in collaboration with the Skolkovo Foundation, we had launched an ‘accelerator’ programme focused on supporting scientists to develop treatments and diagnosis systems for our main therapy areas. Now, this programme is included in the scope of our iDREAM collaboration.
- Brazil, August 2018 – We signed a MOU with the Brazilian Israeli Beneficent Society Albert Einstein to launch the iDREAM hub in Brazil. This collaboration programme focuses on cardiovascular, renal and metabolic diseases, and includes initiatives to foster early- and late-stage clinical development, support innovation through acceleration of start-ups and implement education programmes.
- Taiwan, September 2018 – We signed a Letter of Intent with the Taiwan BioHub, the newly established flagship biopharmaceutical innovation hub of the Taiwanese government, which laid the groundwork for the Taiwan iDREAM hub. Our partner is at the centre of Taiwan’s biomedical ecosystem and gives us access to the national academy of science and other leading biomedical research institutions. Upcoming collaborations will cover digital health, entrepreneurship and advanced R&D topics such as proteogenomics and cardiac drug delivery targets.
- China, March 2019 – We signed a MOU with the Wuxi High-tech District at the Boao Forum for Asia (BFA) Annual Conference to build an International Life Science Innovation Park in conjunction with the Wuxi municipal government. The new Wuxi ecosystem will provide companies with shared resources, including laboratories, equipment and services. It will also facilitate collaboration with AstraZeneca's global R&D network to accelerate innovation, supporting the end-to-end development and commercialisation of medicines in China.
- Argentina, April 2019 – We launched our Argentina iDREAM hub with the signing of a Collaboration Agreement with the Argentinian Ministry of Science, Technology and Productive Innovation to focus on Precision Medicine, which will help to develop new targeted medicines, as well as identifying which patients could benefit from treatments. Several other projects are already in progress, including a partnership with the National Scientific and Technical Research Council (CONICET). This new iDREAM hub paves the way for further collaboration in Argentina, creating more opportunities to accelerate innovation and deliver patient-centric healthcare solutions that address local needs.
- India, April 2019 – The iDREAM hub in India was established as part of the recent expansion of our strategic collaborations to address the rising burden of Non-Communicable Diseases (NCDs) in the country, building on the foundation of the bilateral Innovation Partnership between India and Sweden in 2018. It will complement our strategic partnership with the National Association of Software and Services Companies (NASSCOM), enabling us to run an accelerator for health start-ups in collaboration with NASSCOM’s Centre of Excellence for Internet of Things, the largest platform for deep tech innovation in India. This iDREAM hub will further support the thriving start-up culture in India, enabling us to fund exciting new research and create affordable and accessible healthcare solutions to drive meaningful patient outcomes.